MGC Pharmaceuticals (ASX:MXC) has provided an update on the clinical trials involving the company's novel formula 'ArtemiC' to treat COVID-19 patients.
MGC Pharmaceuticals Ltd (ASX: MXC) has provided an update on its Phase II double-blind, placebo-controlled clinical trial on the company's natural anti-inflammatory formulation 'ArtemiC.'
As we've covered previously, MGC's 'ArtemiC' is designed to treat patients with COVID-19, and on the 20th of August, the novel formula demonstrated a significant clinical improvement in patients infected with COVID-19.
In MGC's recent announcement, the company announced that an ArtemiC Trial had commenced at Rambam Hospital in Israel, with 3 patients enrolled already following receipt of Ethics Committee approval. Rambam Hospital is recognized as one of the leading medical centres in Israel. According to MGC, this commencement at Rambam considerably improves the company's access to patients as Rambam Hospital is a 1,000-bed hospital serving more than two million people in Northern Israel.
Patient recruitment also commenced at the Mahatma Gandhi Mission's Medical College & Hospital in India with the first patients expected to begin treatment imminently. Having completed treatment with 33 patients, across all trial sites, MGC Pharma only requires 17 additional patients to be recruited out of a total of 50 needed to complete the trial. As such, the company expects to conclude its trials in October and have results available in the upcoming November.
Moreover, these additional site locations outside of Israel will help to accelerate MGC's application process for ArtemiC with the US FDA and the European Medical Association (EMA) registration.
Roby Zomer, the Co-founder and Managing Director of MGC Pharma, commented: "We are pleased to commence our clinical trial in India which will provide important wider statistical data required as part of the marketing authorization application for ArtemiC. We are also very pleased to receive the recommendation from the medical teams from the current trial which assisted with the expansion of our clinical trial in Israel to include the Rambam Hospital."
We look forward to updating the market as the trial progresses in both Israel and India. Roby Zomer, the Co-founder and Managing Director of MGC Pharma
Dr Prabhakar Ranjekar, Chief Scientific Officer, Oz Innovative Solutions Pty Ltd, commented: "We are pleased to associate with MGC Pharmaceuticals and commence recruitment of COVID-19 patients in India. Currently, India is the second most affected country by COVID-19 and a successful trial of ArtemiC will provide a better treatment option for the doctors. The Indian trial will also provide a good comparison on the effect of ArtemiC in two diverse populations."
To learn more about MGC Pharma, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors